A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
|
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 50 条
  • [41] A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial)
    Yoshihiro Mise
    Kiyoshi Hasegawa
    Akio Saiura
    Masaru Oba
    Junji Yamamoto
    Yukihiro Nomura
    Tadatoshi Takayama
    Yojiro Hashiguchi
    Masayuki Shibasaki
    Hirohiko Sakamoto
    Seiichi Yamagata
    Nobuyoshi Aoyanagi
    Hironori Kaneko
    Hiroto Koyama
    Shinichi Miyagawa
    Eiji Shinozaki
    Shuntaro Yoshida
    Hiroaki Nozawa
    Norihiro Kokudo
    Annals of Surgical Oncology, 2020, 27 : 4188 - 4195
  • [42] The impact of histologic tumor response on survival of patients treated with neoadjuvant mFOLFOX6 plus bevacizumab for the synchronous liver metastases from colorectal cancer.
    Katayose, Yu
    Ishida, Kazuyuki
    Nakagawa, Kei
    Yamauchi, Junichiro
    Oikawa, Masaya
    Sakurai, Naoki
    Musha, Hiroaki
    Shimamura, Hiromune
    Miura, Koh
    Motoi, Fuyuhiko
    Egawa, Shinichi
    Unno, Michiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [43] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
    Heinrich, Kathrin
    Heinemann, Volker
    Westphalen, Benedikt
    Oecal, Osman
    Van Hazel, Guy A.
    Gibbs, Peter
    Seidensticker, Max
    Ricke, Jens
    Seidensticker, Ricarda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers
    Nagayama, Satoshi
    Hasegawa, Suguru
    Hida, Koya
    Kawada, Kenji
    Hatano, Etsuro
    Nakamura, Kojiro
    Seo, Satoru
    Taura, Kojiro
    Yasuchika, Kentaro
    Matsuo, Takashi
    Zaima, Masazumi
    Kanazawa, Akiyoshi
    Terajima, Hiroaki
    Tada, Masaharu
    Adachi, Yukihito
    Nishitai, Ryuta
    Manaka, Dai
    Yoshimura, Tsunehiro
    Doi, Koji
    Horimatsu, Takahiro
    Mitsuyoshi, Akira
    Yoshimura, Kenichi
    Niimi, Miyuki
    Matsumoto, Shigemi
    Sakai, Yoshiharu
    Uemoto, Shinji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 316 - 323
  • [45] Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers
    Satoshi Nagayama
    Suguru Hasegawa
    Koya Hida
    Kenji Kawada
    Etsuro Hatano
    Kojiro Nakamura
    Satoru Seo
    Kojiro Taura
    Kentaro Yasuchika
    Takashi Matsuo
    Masazumi Zaima
    Akiyoshi Kanazawa
    Hiroaki Terajima
    Masaharu Tada
    Yukihito Adachi
    Ryuta Nishitai
    Dai Manaka
    Tsunehiro Yoshimura
    Koji Doi
    Takahiro Horimatsu
    Akira Mitsuyoshi
    Kenichi Yoshimura
    Miyuki Niimi
    Shigemi Matsumoto
    Yoshiharu Sakai
    Shinji Uemoto
    International Journal of Clinical Oncology, 2017, 22 : 316 - 323
  • [46] A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer.
    Li, Chunjie
    Noonan, Anne M.
    Hays, John L.
    Roychowdhury, Sameek
    Malalur, Pannaga G.
    Elkhatib, Rifat T.
    Manne, Ashish
    Mittra, Arjun
    Rahman, Shafia
    Phelps, Mitch A.
    Liang, Beiyuan
    Storts, Hadyen
    Khan, Misbah
    Zhang, Evan
    Zheng, Xinru
    Miles, Wayne
    Wang, Jing
    Jin, Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 101 - 101
  • [47] A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
    Nishina, Tomohiro
    Takano, Yoshinao
    Denda, Tadamichi
    Yasui, Hisateru
    Takeda, Koji
    Ura, Takashi
    Esaki, Taito
    Okuyama, Yusuke
    Kondo, Ken
    Takahashi, Yasuo
    Sugiyama, Yasuyuki
    Muro, Kei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1080 - 1086
  • [48] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)
    van Hazel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059
  • [49] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera A.
    Karapetis, Christos Stelios
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345